MedTrace Logo

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

NCT03553537 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-06-12

No results posted yet for this study

Summary

Primary objective of the study is to compare the efficacy and safety of decitabine plus CHOP (D-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL).

Conditions

  • Peripheral T-cell Lymphoma

Interventions

DRUG

Decitabine

10mg/m² iv on day 1-5

DRUG

Cyclophosphamide

750mg/m² iv on day 6

DRUG

Doxorubicin

DOX

DRUG

Vincristine

1.4mg/m² iv on day 6

DRUG

Prednisone

100mg/m² po on day6-10

Sponsors & Collaborators

  • Southwest Hospital, China

    lead OTHER

Principal Investigators

  • Jieping Chen, MD,PhD · Southwest Hospital, China

  • Xi Li, MD · Southwest Hospital, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-30
Primary Completion
2021-07-31
Completion
2021-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553537 on ClinicalTrials.gov